Contact us

To find out more please contact us via the form or call: +44 (0) 333 566 0340


  • * Required fields
  • This field is for validation purposes and should be left unchanged.

The day after biotech firm Bristol-Myers Squibb (BMS) announced a proposed acquisition of pharma company Celgene, news headlines focused on the particulars of the deal, and the potential for the first big acquisition of 2019 to be a catalyst for biotech takeovers in the coming year. The BMS news certainly started the new year off with a bang, continuing a trend from 2018 in which merger and acquisition (M&A) activity was high, with worldwide deals valued at nearly $4 trillion according to the Institute for Mergers, Acquisitions and Alliances (IMAA).

Contacts

William Strange

Principal and Consulting Actuary, Milliman

VIEW PROFILE

Contacts

William Strange

Principal and Consulting Actuary, Milliman

VIEW PROFILE